GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Net Issuance of Debt

Rize Oncology (XCNQ:RIZE) Net Issuance of Debt : C$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Rize Oncology's net issuance of debt for the three months ended in Dec. 2024 was C$0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil.

Rize Oncology Net Issuance of Debt Historical Data

The historical data trend for Rize Oncology's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Net Issuance of Debt Chart

Rize Oncology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
0.13 - - - -

Rize Oncology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rize Oncology Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rize Oncology Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rize Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Net Issuance of Debt
Comparable Companies
XCNQ:MBIO XCNQ:MOOD XCNQ:HEAL XCNQ:ENBI TSXV:WAVE XCNQ:NSHS XCNQ:NIRV XCNQ:CHGX XCNQ:AGN XCNQ:MYND VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1
Website
https://www.rizeoncology.com
Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.
Executives
William James Garner 10% Security Holder, Director

Rize Oncology Headlines

No Headlines